Live Therapeutics for Better Life
Formulating Digital Therapies One Person at a Time
The Dario Difference
DarioHealth delivers evidence-based, personalized digital therapeutic interventions for the chronic condition spectrum, giving people the tools, technology, data, and support they need to manage their health every day.
DarioHealth Corp. is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day in age, knowledge of health and treatment is being democratized and we believe people deserve to know everything about their own health, and at the same time have the best tools to manage their treatment.
DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed unique ways for people to analyze and personalize their chronic disease management. DarioHealth’s approach has taken the best of both worlds – the world of the wearable market, which is projected to reach $51.6B in just a few years, and the monitoring market that is climbing toward the $30B mark* – and flipped traditional health upside down. We are moving from periodic data to continuous data, from general treatment to personalized treatment, and from theory-driven solutions to adapted data & AI/ML technology. DarioHealth’s solutions span the full spectrum of disease monitoring, management, populations, and engagement.
What truly makes DarioHealth a remarkable investment opportunity is the fact that it has steadily grown from being a user-centric, direct-to-consumer company to a mature organization that is fully data-driven and able to provide a wide-range of managed care solutions. At the hub of it all is DarioHealth’s proprietary engagement platform, which has been painstakingly built by carefully monitoring and analyzing big data. Today, DarioHealth boasts phenomenal solutions and automated, full-suite services for the biggest players in the diabetes care management space.
Dario Blood Glucose Monitoring System
Smart pocket-sized device.
Fit for anyone, everywhere, and on the go.
Highly accurate and fast measurements.
Get results in less than 6 seconds.
Small drop of blood – only 0.3 μl required.
No cables, no batteries, no hassles.
Automatically records your blood glucose measurements and provides analysis of your condition.
Easily tracks key diabetes metrics, including carb counting, physical activity, and medication intake.
Share real-time information and personalized reports with caregivers and family members.
Built-in emergency hypo alert with GPS location for peace of mind.
With tens of thousands of active users worldwide and proven clinical outcomes, DarioHealth is a global digital therapeutics solution leader revolutionizing the way people manage their chronic conditions.
Built for and around the user, Dario has created individualized solutions that combine best practices in digital technologies, analytics, hardware, and personal coaching that gently instructs, encourages, and inspires users…
To self-manage their health day to day.
What Makes Dario Different?
At Dario, the user always comes first. From designing the medical hardware and mobile applications to defining the communications and coaching, Dario’s goal is to create solutions that engage, inspire and motivate users to make Dario a part of their daily journey towards healthy living.
Every user is different. And every day is different. When self-monitoring a chronic condition, having accurate, personal information available in real-time is critical for adapting to the fluctuations of daily life.
Who Is Dario For?
People who want to understand how their everyday life impacts their personal health, and what actions they can take to improve their health, how to better collaborate with healthcare providers and to live their life on their own terms.
Businesses looking to increase employee satisfaction, loyalty, and productivity with fewer health-related absences can take advantage of Dario’s services for employers.
Healthcare Providers wanting to boost patient compliance will find that Dario’s interactive services allow for greater monitoring capabilities, and the means to engage with patients to offer the right treatment at the right time.
Health Plans seeking better patient outcomes and lower costs will value Dario’s solutions that encourage patients to be more involved in managing their conditions, and proactively take preventative measures that reduce risk, emergency room visits, and preventable hospitalization.
And the results speak for themselves. Dario’s user-focused, user-friendly solutions have been shown to help people achieve better health outcomes*. By creating state-of-the-art solutions that help people improve their quality of life, Dario is helping to create a happier, healthier world, one person at a time.
* Reference, ADA Poster: “T2D Users of a Digital Diabetes Management System Experience a Shift from Greater than 180 mg/dL to Normal Glucose Levels with Sustainable Results” (ADA 2018 76-LB)
A Personal Approach with Global Reach
The world leading Dario Blood Glucose Monitoring System has US FDA clearance and approval from the European CE, Health Canada, and Australia’s TGA. It is commercially available in the United States, Canada, the United Kingdom, Germany, Italy, and Australia.
DarioHealth is rapidly moving into new geographic markets and chronic conditions such as hypertension, stress management and obesity.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated twenty five hundred dollars for DarioHealth Corp. current news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF DarioHealth Corp.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.